Skip to main content

Table 3 Grade 3/4 AEs occurring in ≥ 2% of patientsa

From: Efficacy and safety of pomalidomide and low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: a multicenter, prospective, single-arm, phase 2 trial

 

Total

Grade 3

Grade 4

Hematologic TEAEs

 Neutropenia

64(86.49)

31(41.89)

16(21.62)

 Leukopenia

64(86.49)

26(35.14)

2(2.70)

 Thrombocytopenia

58(78.38)

14(18.92)

7(9.46)

 Anemia

50(67.57)

22(29.73)

1(1.35)

 Lymphocytopenia

37(50.00)

10(13.51)

5(6.76)

Non-hematologic TEAEs

 Hypoalbuminemia

38(51.35)

2(2.70)

0

 Hyperglycemia

34(45.95)

4(5.41)

0

 Proteinuria

32(43.24)

3(4.05)

0

 Upper respiratory tract infection

28(37.84)

2(2.70)

0

 Pyrexia

21(28.38)

3(4.05)

0

 Pulmonary infection

21(28.38)

19(25.68)

1(1.35)

 Hyperuricemia

18(24.32)

1(1.35)

2(2.70)

 Reduced creatinine clearance (< 60 mL/min/1.73 m2)

17(22.97)

2(2.70)

0

 Hypophosphatemia

10(13.51)

3(4.05)

0

  1. aUnless otherwise noted, all data are n(%)